Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancrea
 

Celgene International SÃ*rl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

More...